^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Hensify (crystalline hafnium oxide)

    i
    Other names: JNJ1900, JNJ 1900, JNJ-90301900, NBTXR3, PEP503, PEP-503, NBTXR 3, NBTX 3, NBTXR-3, JNJ-1900
    Associations

    News

    Trials
    Company:
    J&J, LianBio, Nanobiotix
    Drug class:
    Free radical stimulant, Radiosensitiser
    Related drugs:
    Associations

    News

    Trials
    24d
    NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 34
    Enrollment closed • Enrollment change
    |
    Hensify (crystalline hafnium oxide)
    1m
    NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Hensify (crystalline hafnium oxide)
    1m
    NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical • Hensify (crystalline hafnium oxide)
    1m
    Study 1100: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (clinicaltrials.gov)
    P1, N=145, Active, not recruiting, Nanobiotix | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Aug 2027
    Enrollment closed • Trial completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hensify (crystalline hafnium oxide)
    1m
    A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Johnson & Johnson Enterprise Innovation Inc.
    New P1 trial
    |
    Hensify (crystalline hafnium oxide)
    4ms
    NANORAY-312: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Jun 2027 --> Dec 2027
    Trial completion date
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)
    6ms
    NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, M.D. Anderson Cancer Center | N=60 --> 14 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Hensify (crystalline hafnium oxide)
    1year
    NANORAY-312: NBTXR3 With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Nanobiotix | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Jul 2024 --> Jun 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)
    1year
    NCI-2020-03731: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Hensify (crystalline hafnium oxide)
    1year
    Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3. (PubMed, J Nanobiotechnology)
    Mice achieving remission through NBTXR3 + PRT + αPD1 exhibited a robust memory immune response, effectively inhibiting growth of subsequent tumors from three distinct lung cancer cell lines. Proton IRT combined with NBTXR3 offers enhanced tumor control and survival rates over photon-based treatments in managing αPD1-resistant lung cancer, indicating its potential as a potent systemic therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • NKG7 (Natural Killer Cell Granule Protein 7)
    |
    IFNG expression
    |
    Hensify (crystalline hafnium oxide)
    over1year
    NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Hensify (crystalline hafnium oxide)
    over1year
    NCI-2020-03731: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Hensify (crystalline hafnium oxide)